Investment
Features
FeesSafety
Academy
More
Pluang+

Nearly 45% of US home sales in August included seller concessions, highest since 2020.

Market News
18 Sep 2026
PRNewsWire
View Source
Neutral
Nearly 45% of US home sales in August included seller concessions, highest since 2020.

In August 2026, 44.7% of U.S. home sales involved seller concessions, the highest August rate since 2020, reflecting a strong buyer's market with more homes for sale and fewer buyers. Concessions are especially common in Sun Belt cities like Atlanta and Nashville, where about 70% of buyers receive them, as sellers compete to close deals amid abundant listings. Conversely, markets like San Jose and New York see fewer concessions due to stronger seller conditions. Additionally, about 15% of buyers benefit from both concessions and price cuts, signaling ongoing seller incentives to attract buyers.

Nearly half of U.S. homebuyers received seller concessions in August 2026, with 44.7% of sales involving such deals, the highest August rate since 2020. For readers following the U.S. real estate sector, here is Pluang's market snapshot as of Sep 18, 2026 17:42 WIB: out of 24 priced real estate stocks, 16 rose and 6 fell. Notable movers include AIV at USD 2.23 (+0.45%), AMH at USD 31.40 (+0.38%), and AGNC at USD 9.94 (+0.30%), with typical hold times ranging from 71 to 102 days and varied Pluang order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin's price surged from around $76,400 to nearly $81,000 on September 18, 2026, driven by a rapid liquidation of $192 million in leveraged crypto positions, including $183 million in short bets. This forced buying pushed Bitcoin above $80,000 for...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App